Table 3.
Specific characteristics related to COVID-19, by antibody concentration.
| Total n=585 | Antibody concentrations < 15 n = 139 | Antibody concentrations ≥15 n = 446 | p-value | |
|---|---|---|---|---|
| Disease onset date | ||||
| March 2020 | 382 (65.4%) | 86 (61.9%) | 296 (66.5%) | |
| April 2020 | 150 (25.7%) | 38 (27.3%) | 112 (25.2%) | |
| May 2020 | 26 (4.5%) | 8 (5.8%) | 18 (4.0%) | |
| June 2020 | 26 (4.5%) | 7 (5.0%) | 19 (4.3%) | |
| COVID-19 symptoms | 0.033 b | |||
| Asymptomatic | 109 (18.7%) | 35 (25.2%) | 74 (16.6%) | |
| Symptomatic | 475 (81.3%) | 104 (74.8%) | 371 (83.4%) | |
| Number of symptoms | < 0.001 c | |||
| 0–2 | 290 (49.6%) | 91 (65.5%) | 199 (44.6%) | |
| 3–4 | 201 (34.4%) | 35 (25.2%) | 166 (37.2%) | |
| 5–6 | 94 (16.1%) | 13 (9.4%) | 81 (18.2%) | |
| Fever e | 228 (48.0%) | 31 (29.8%) | 197 (53.0%) | < 0.001 a |
| Cough e | 265 (55.8%) | 52 (50.0%) | 213 (57.3%) | 0.219a |
| Muscle pain e | 312 (65.6%) | 58 (55.8%) | 254 (68.3%) | 0.02 a |
| Headache e | 272 (57.1%) | 49 (47.1%) | 223 (60.0%) | 0.025 a |
| Shortness of breath e | 92 (19.3%) | 19 (18.3%) | 73 (19.6%) | 0.888a |
| Loss of taste or smell e | 310 (65.1%) | 58 (55.8%) | 252 (67.7%) | 0.027 a |
| COVID-19 severity | 0.094c | |||
| Asymptomatic, Mild to Moderate | 534 (91.8%) | 132 (95.7%) | 402 (90.5%) | |
| Severe | 38 (6.5%) | 6 (4.4%) | 32 (7.2%) | |
| Critical | 10 (1.7%) | - | 10 (2.3%) | |
| Isolation/treatment site | 0.1a | |||
| House | 534 (91.8%) | 132 (95.7%) | 402 (90.5%) | |
| Hospitalized | 48 (8.3%) | 6 (4.4%) | 42 (9.5%) | |
| Number of days in hospital d (mean ± sd) | 14.3 ± 12.5 | 8.2 ± 6.4 | 15.1 ± 12.9 | 0.006 b |
| Comparing to your health before | 0.019 c | |||
| getting sick with COVID-19, how | ||||
| do you feel now | ||||
| Better | 53 (9.1%) | 11 (8.0%) | 42 (9.5%) | |
| Equal | 377 (65.0%) | 103 (74.6%) | 274 (62.0%) | |
| Worst | 150 (25.9%) | 24 (17.4%) | 126 (28.5%) |
aFisher's exact test; bt-test; cPearson chi-square, dFever, Cough, Muscle pain, Headache, Shortness of breath and loss of taste or loss of smell only for participants with symptomatic disease; eNumber of days in hospital, only for participants who were hospitalized.
Statistically significant values are denoted in bold. Entries are n (%) unless otherwise stated.
Sample size is not constant due to missing data.
Total: Disease onset date (n = 584); Type of disease (n = 585); Fever (n = 475); Cough (n = 475); Muscle pain (n = 475); Headache (n = 475); Shortness of breath (n = 475); Loss of taste or loss of smell (n=475); Severity (n = 578); Isolation/treatment site (n = 582); Number of days in hospital (n = 48); Health condition (n = 580).
Antibody concentrations < 15: Disease onset date (n = 139); Type of disease (n = 139); Fever (n = 104); Cough (n = 104); Muscle pain (n = 104); Headache (n = 104); Shortness of breath (n = 104); Loss of taste or loss of smell (n = 104); Severity (n = 138); Isolation/treatment site (n = 138); Number of days in hospital (n = 6); Health condition (n = 138).
Antibody concentrations ≥15: Disease onset date (n = 445); Type of disease (n = 445); Fever (n = 371); Cough (n = 371); Muscle pain (n = 371); Headache (n = 104); Shortness of breath (n = 371); Loss of taste or loss of smell (n = 371); Severity (n = 440); Isolation/treatment site (n = 444); Number of days in hospital (n = 42); Health condition (n = 442).